Extrawell Pharmaceutical Holdings Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Extrawell Pharmaceutical Holdings's earnings have been declining at an average annual rate of -30.3%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been declining at an average rate of 5.9% per year.
Anahtar bilgiler
-30.3%
Kazanç büyüme oranı
-30.3%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 5.6% |
| Gelir büyüme oranı | -5.9% |
| Özkaynak getirisi | -14.5% |
| Net Marj | -275.7% |
| Son Kazanç Güncellemesi | 31 Mar 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt
Mar 18
Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt
Dec 01We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings
Aug 04Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?
Mar 15Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year
Aug 20Gelir ve Gider Dağılımı
Extrawell Pharmaceutical Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 24 | 59 | -163 | 35 | 0 |
| 31 Dec 23 | 64 | -159 | 37 | 0 |
| 30 Sep 23 | 69 | -154 | 39 | 0 |
| 30 Jun 23 | 71 | -13 | 41 | 0 |
| 31 Mar 23 | 73 | 129 | 42 | 0 |
| 31 Dec 22 | 69 | 109 | 43 | 0 |
| 30 Sep 22 | 65 | 88 | 44 | 0 |
| 30 Jun 22 | 69 | 109 | 47 | 0 |
| 31 Mar 22 | 74 | 131 | 50 | 0 |
| 31 Dec 21 | 80 | 12 | 54 | 0 |
| 30 Sep 21 | 86 | -107 | 57 | 0 |
| 30 Jun 21 | 82 | -114 | 55 | 0 |
| 31 Mar 21 | 79 | -121 | 53 | 0 |
| 31 Dec 20 | 76 | 6 | 52 | 0 |
| 30 Sep 20 | 74 | 133 | 51 | 0 |
| 30 Jun 20 | 76 | 108 | 51 | 0 |
| 31 Mar 20 | 78 | 83 | 51 | 0 |
| 31 Dec 19 | 81 | 73 | 55 | 0 |
| 30 Sep 19 | 85 | 63 | 59 | 0 |
| 30 Jun 19 | 87 | 63 | 63 | 0 |
| 31 Mar 19 | 89 | 64 | 67 | 0 |
| 31 Dec 18 | 86 | 51 | 64 | 0 |
| 30 Sep 18 | 83 | 39 | 61 | 0 |
| 30 Jun 18 | 85 | 34 | 60 | 0 |
| 31 Mar 18 | 86 | 30 | 59 | 0 |
| 31 Dec 17 | 88 | 32 | 58 | 0 |
| 30 Sep 17 | 91 | 34 | 57 | 0 |
| 30 Jun 17 | 100 | 27 | 58 | 0 |
| 31 Mar 17 | 108 | 21 | 59 | 0 |
| 31 Dec 16 | 116 | 46 | 61 | 0 |
| 30 Sep 16 | 125 | 71 | 64 | 0 |
| 30 Jun 16 | 133 | 52 | 66 | 0 |
| 31 Mar 16 | 142 | 33 | 69 | 0 |
| 30 Sep 15 | 136 | -81 | 60 | 2 |
| 30 Jun 15 | 132 | -63 | 61 | 2 |
| 31 Mar 15 | 129 | -44 | 62 | 2 |
| 30 Sep 14 | 155 | 13 | 98 | 0 |
| 30 Jun 14 | 153 | 13 | 87 | 0 |
| 31 Mar 14 | 151 | 14 | 76 | 0 |
| 31 Dec 13 | 144 | 11 | 42 | 4 |
Kaliteli Kazançlar: 858 is currently unprofitable.
Büyüyen Kar Marjı: 858 is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 858 is unprofitable, and losses have increased over the past 5 years at a rate of 30.3% per year.
Büyüme Hızlandırma: Unable to compare 858's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: 858 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).
Özkaynak Getirisi
Yüksek ROE: 858 has a negative Return on Equity (-14.53%), as it is currently unprofitable.